Preclinical Evaluation of a [sup.64]Cu-Based Theranostic Approach in a Murine Model of Multiple Myeloma

Although the concept of theranostics is neither new nor exclusive to nuclear medicine, it is a particularly promising approach for the future of nuclear oncology. This approach is based on the use of molecules targeting specific biomarkers in the tumour or its microenvironment, associated with optim...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2023-06, Vol.15 (7)
Main Authors: Métivier, Cassandra, Le Saëc, Patricia, Gaschet, Joëlle, Chauvet, Catherine, Marionneau-Lambot, Séverine, Hofgaard, Peter O, Bogen, Bjarne, Pineau, Julie, Le Bris, Nathalie, Tripier, Raphaël, Alliot, Cyrille, Haddad, Férid, Chérel, Michel, Chouin, Nicolas, Faivre-Chauvet, Alain, Rbah-Vidal, Latifa
Format: Article
Language:English
Subjects:
Ethylenediaminetetraacetic acid
Multiple myeloma
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although the concept of theranostics is neither new nor exclusive to nuclear medicine, it is a particularly promising approach for the future of nuclear oncology. This approach is based on the use of molecules targeting specific biomarkers in the tumour or its microenvironment, associated with optimal radionuclides which, depending on their emission properties, allow the combination of diagnosis by molecular imaging and targeted radionuclide therapy (TRT). Copper-64 has suitable decay properties (both β[sup.+] and β- decays) for PET imaging and potentially for TRT, making it both an imaging and therapy agent. We developed and evaluated a theranostic approach using a copper-64 radiolabelled anti-CD138 antibody, [[sup.64]Cu]Cu-TE1PA-9E7.4 in a MOPC315.BM mouse model of multiple myeloma. PET imaging using [[sup.64]Cu]Cu-TE1PA-9E7.4 allows for high-resolution PET images. Dosimetric estimation from ex vivo biodistribution data revealed acceptable delivered doses to healthy organs and tissues, and a very encouraging tumour absorbed dose for TRT applications. Therapeutic efficacy resulting in delayed tumour growth and increased survival without inducing major or irreversible toxicity has been observed with 2 doses of 35 MBq administered at a 2-week interval. Repeated injections of [[sup.64]Cu]Cu-TE1PA-9E7.4 are safe and can be effective for TRT application in this syngeneic preclinical model of MM.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics15071817